Medical progress: Sudden death due to cardiac arrhythmias

New England Journal of Medicine

Volumn 345, Issue 20, 2001, Pages 1473-1482

  Huikuri, Heikki V ^a   Castellanos, Agustin ^a,b   Myerburg, Robert J ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR FUNCTION; ELECTROCARDIOGRAPHY; EPIDEMIOLOGY; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; INCIDENCE; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SUDDEN DEATH; CARDIOMYOPATHY; DEFIBRILLATOR; HEART RATE; HUMAN; PROGNOSIS; RISK FACTOR;

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC BETA-ANTAGONISTS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; BAROREFLEX; CARDIOMYOPATHIES; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; PRIMARY PREVENTION; PROGNOSIS; RISK FACTORS;

EID: 0035891624     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra000650     Document Type: Review

References (97)

1. Sudden cardiac death: Epidemiology, transient risk, and intervention assessment
2. Frequency of sudden cardiac death and profiles of risk
3. Sudden cardiac death
4. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The cardiac arrhythmia suppression trial
5. Effect ofd-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
6. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia
7. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
8. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
9. A randomized study of the prevention of sudden death in patients with coronary artery disease
10. Interpretation of outcomes of antiarrhythmic clinical trials: Design features and population impact
11. Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction
12. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases
13. Sudden death in coronary artery disease: Acute ischemia versus myocardial substrate
14. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure
15. Classification of death in antiarrhythmia trials
16. Exploration of the precision of classifying sudden cardiac death: Implications for the interpretation of clinical trials
17. Anatomic features in victims of sudden coronary death: Coronary artery pathology
18. Sudden cardiac death: Structure, function, and time-dependence of risk
19. Risk stratification and survival after myocardial infarction
20. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction
21. Role of left ventricular ejection fraction
22. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure
23. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCDHEFT and MADIT-II
24. A biological approach to sudden cardiac death: Structure, function and cause
25. Origins, classification, and significance of ventricular arrhythmias
26. Ventricular premature complexes and sudden death after myocardial infarction
27. Predictors of arrhythmic death and cardiac arrest in the ESVEM trial: Electrophysiologic study versus electromagnetic monitoring
28. Predictors of total mortality and sudden death in mild to moderate heart failure
29. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era: GISSI-2 results
30. Nonsustained ventricular tachycardia in severe heart failure: Independent marker of increased mortality due to sudden death
31. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy
32. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death
33. What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction?
34. Survival after resuscitation from out-of-hospital ventricular fibrillation
35. Influence of the genotype on the clinical course of the long-QT syndrome
36. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: Review for the clinician
37. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy
38. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and leectrocardiographic syndrome: A multicenter report
39. Standards for analysis of ventricular late potentials using high resolution or signal-averaged electrocardiography: A statement by a task force committee between the European society of cardiology, the American heart association and the American college of cardiology
40. Definition of the best prediction criteria of the time-domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period
41. The prognostic significance of quantitative signal-averaged variables relative to clinical variables, site of myocardial infarction, ejection fraction and ventricular premature beats: A prospective study
42. Predicting arrhythmic events after acute myocardial infarction using the signal-averaged electrocardiogram
43. Value of signal-averaged electrocardiography, radionuclide ventriculography, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thrombolytic era
44. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: Based on signal-averaged electrocardiogram, radionuclide ejection fraction and Holter monitoring
45. QT dispersion: An indication of arrhythmia risk in patients with long QT intervals
46. Electrical alternans and cardiac electrical instability
47. Electrocardiographic indexes of dispersion of ventricular repolarization: An isolated heart validation study
48. QT dispersion and mortality after myocardial infarction
49. QT dispersion and sudden unexpected death in chronic heart failure
50. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction
51. QT-dispersion: Problems of methodology and clinical significance
52. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: Results of a prospective, long-term follow-up study
53. Predicting sudden cardiac death from T wave alternans of the surface electrocardiogram: Promise and pitfalls
54. Electrical alternans and vulnerability to ventricular arrhythmias
55. Electrical alternans during rest and exercise as predictors of vulnerability to ventricular arrhythmias
56. Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure
57. T wave alternans as a predictor of recurrent ventricular tachyarrhythmias in ICD recipients: Prospective comparison with conventional risk markers
58. T-wave alternans and dispersion of the QT interval as risk stratification markers in patients susceptible to sustained ventricular arrhythmias
59. Significance of ventricular arrhythmias initiated by programmed ventricular stimulation: The importance of the type of ventricular arrhythmia induced and the number of premature stimuli required
60. Recent insights in programmed electrical stimulation for the management of sustained ventricular arrhythmias
61. Electrophysiologic testing and follow-up of patients with aborted sudden death
62. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias
63. Long-term outcome of patients with unexplained syncope treated with an electrophysiologic-guided approach in the implantable cardioverter-defibrillator era
64. Electrophysiologic-electropharmacologic testing in patients with ventricular arrhythmias
65. Implantable cardioverter-defibrillator therapy in survivors of out-of-hospital sudden cardiac death without inducible arrhythmias
66. Cost effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors: A randomized study
67. Programmed ventricular stimulation in survivors of an acute myocardial infarction
68. Value of programmed ventricular stimulation in predicting sudden death and sustained ventricular tachycardia in survivors of acute myocardial infarction
69. Autonomic nervous system and sudden cardiac death: Experimental basis and clinical observations for postmyocardial infarction risk stratification
70. Decrease heart rate variability and its association with increased mortality after acute myocardial infarction
71. Frequency domain measures of heart period variability and mortality after myocardial infarction
72. Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era: The GISSI-2 results
73. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction
74. Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-Heart)
75. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction
76. Measurement of heart rate variability: A clinical tool or a research toy?
77. Impact of reduced heart rate variability on risk for cardiac events: The Framingham Heart Study
78. Heart rate variability and dispersion of QT interval in patients with vulnerability to ventricular tachycardia and ventricular fibrillation after previous myocardial infarction
79. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results
80. Beta blockade during and after myocardial infarction: An overview of the randomized trials
81. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
82. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT
83. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT
84. Amiodarone interaction with beta-blockers: Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases
85. Prophylactic use of implantable cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery
86. Clinical trials of implantable defibrillators
87. The implantable cardioverter defibrillator and primary prevention of sudden death: The Multicenter Automatic Defibrillator Implantation Trial and the Coronary Artery Bypass Graft (CABG)-Patch Trial
88. Is screening of patients fulfilling the MADIT criteria after a prior myocardial infarction cost-effective?
89. Implantable cardioverter-defibrillators
90. Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone
91. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH)
92. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias
93. Family history as a risk factor for primary cardiac arrest
94. Predicting sudden death in the population: The Paris prospective study I
95. Sudden cardiac death: Exploring the limits of our knowledge
96. Fascinating rhythm: A primer on chaos theory and its application to cardiology
97. Chaos and the transition to ventricular fibrillation: A new approach to antiarrhythmic drug evaluation